5 Articles
5 Articles
Hospital uses insulin-producing iPS cells for type 1 diabetes
A Japanese hospital said Monday it has completed a clinical test to transplant induced pluripotent stem cells that produce insulin to treat a patient with type 1 diabetes, in a step that could ease the burden of injecting daily insulin shots. Kyoto University Hospital performed the surgery in February using…
Japan hospital uses insulin-producing iPS cells for type 1 diabetes
A Japanese hospital said Monday it has completed a clinical test to transplant induced pluripotent stem cells that produce insulin to treat a patient with type 1 diabetes, in a step that could ease the burden of injecting daily insulin shots. Kyoto University Hospital performed the surgery in February using iPS cell-derived pancreatic islet cells to confirm the safety of the procedure for the autoimmune disease, which prevents the pancreas from …
First case of iPS cell transplant completed for diabetes treatment at Kyoto University
Kyoto University Hospital (Kyoto City) announced on the 14th that it has completed the first transplant in a clinical trial to transplant pancreatic cells made from iPS cells into a diabetic patient. The progress is said to be going well, and there are no safety issues at this time. A second transplant will be carried out soon. There are two types of diabetes: type 2, which occurs when pancreatic function is reduced due to lifestyle-related dise…
Cellino, Karis Bio Partner on Autologous iPSC-Based Therapy for Cardiovascular Disease
Cellino, a biotechnology firm working on autonomous biomanufacturing for personalized regenerative medicines, has signed a strategic collaboration with Karis Bio, a South Korean cell therapy company, that will allow it to expand into the Asia-Pacific region. The partners aim to industrialize what they claim will be the first clinical-stage autologous induced pluripotent stem cell-derived (iPSC) therapy for peripheral artery disease and coronary …
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage